Importantly, sEH inhibition reduces inflammation in mouse models of multiple diseases, including atherosclerosis, abdominal aortic aneurysm, dyslipidemia, hypertension, and diabetes (62, 65). Here, EPHX2 is linked to diabetes mellitus.